Health Technology

Takeda Pharmaceutical Co., Ltd.

In the news

Takeda offers early retirement to workers as young as 30 Aug 18, 2020
AstraZeneca to supply Japan with 120m COVID-19 vaccine doses Aug 8, 2020
Takeda starts trials of 3 COVID drugs in US with Amgen and AbbVie Aug 5, 2020
Japan Inc says goodbye downtown, hello suburbs in post-pandemic era Jul 11, 2020
Japan and Western drugmakers launch $1bn fund against superbugs Jul 10, 2020

See more articles on Takeda Pharmaceutical Co., Ltd.

Business Summary

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2022	JPY	USD
Revenue	3,569.00B	31,760.44M
Gross Profit	2,043.63B	18,186.20M
Operating income	610,496M	5,432.77M
Income before tax	317,938M	2,829.31M
Net income	230,059M	2,047.28M
EBITDA	1,193.64B	10,622.21M
Diluted EPS	145.86	1.29
Dividends Per Share	180	1.60
Total Assets	13,178.01B	108,572.75M
Total liabilities	7,494.49B	61,746.62M
Total equity	5,683.01B	46,821.99M
Operating cash flow	1,021.21B	9,087.77M
	Currency in JPY	Currency in USD

Historical Data

JPY | USD

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Revenue	1,770.53B	2,097.22B	3,291.18B	3,197.81B	3,569.00B
Gross Profit	1,148.86B	1,275.55B	1,789.37B	1,798.37B	2,043.63B
Operating income	195,320M	218,686M	302,612M	447,610M	610,496M
Income before tax	217,205M	127,612M	-60,754M	366,159M	317,938M
Net income	186,886M	135,192M	44,241M	376,005M	230,059M
EBITDA	377,447M	466,377M	886,261M	1,007.28B	1,193.64B
Diluted EPS	237.55	139.82	28.24	238.95	145.86
Dividends Per Share	180	180	180	180	180
Total Assets	4,106.46B	13,792.77B	12,821.09B	12,912.29B	13,178.01B
Total liabilities	2,089.05B	8,606.78B	8,093.60B	7,735.11B	7,494.49B
Total equity	1,997.42B	5,181.98B	4,723.48B	5,173.03B	5,683.01B
Operating cash flow	379,600M	302,609M	555,410M	905,073M	1,021.21B

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Revenue	15,974.84M	18,911.85M	30,270.54M	30,151.70M	31,760.44M
Gross Profit	10,365.80M	11,502.42M	16,457.72M	16,956.61M	18,186.20M
Operating income	1,762.30M	1,972.01M	2,783.25M	4,220.44M	5,432.77M
Income before tax	1,959.76M	1,150.74M	-558.78M	3,452.46M	2,829.31M
Net income	1,686.20M	1,219.10M	406.90M	3,545.29M	2,047.28M
EBITDA	3,405.56M	4,205.58M	8,151.34M	9,497.50M	10,622.21M
Diluted EPS	2.14	1.26	0.25	2.25	1.29
Dividends Per Share	1.62	1.62	1.65	1.69	1.60
Total Assets	38,612.71M	124,612.85M	118,763.31M	116,853.33M	108,572.75M
Total liabilities	19,643.19M	77,759.25M	74,972.05M	70,001.05M	61,746.62M
Total equity	18,781.60M	46,817.41M	43,754.18M	46,814.81M	46,821.99M
Operating cash flow	3,424.99M	2,728.79M	5,108.35M	8,533.80M	9,087.77M

Valuation Measures

Mar 2022
PER	23.77
ROA	1.76%
ROE	4.23%
Operating margin	17.10%
Profit margin	6.44%

Key executives

President, CEO & Representative Director: Christophe Weber
Chief Financial Officer & Director: Constantine Saroukos
Director, President-Research & Development: Andrew S. Plump
Chief Medical & Scientific Officer: Michael E. Mendelsohn
Chief Accounting Officer & Corporate Controller: Norimasa Takeda

Shareholders

Nomura Asset Management Co., Ltd. (4.2%)
Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.8%)
BlackRock Fund Advisors (3.2%)
The Vanguard Group, Inc. (2.5%)
Nikko Asset Management Co., Ltd. (2.0%)
Daiwa Asset Management Co. Ltd. (1.9%)
Nippon Life Insurance Co. (1.8%)
Norges Bank Investment Management (1.4%)
BlackRock Japan Co., Ltd. (1.4%)
Takeda Pharmaceutical Co., Ltd. (1.3%)

Contact Details

Website:http://www.takeda.co.jp
Address: 4-1-1 Dosho-machi, Chuo-Ku, Osaka, 540-8645, Japan
Phone: +81.6.6204.2111

Related Companies

Takeda Pharmaceutical Co. Ltd. /Life Science Park Ops/
Takeda Pharmaceutical Co Ltd /Asker Pharma Manufacturing Ops/
Takeda Digital Ventures
Takeda Pharmaceutical Co. Ltd. /5 Prescription Pharma Asset/
Takeda Pharmaceutical Employee Long Term Incentive Plan
Takeda Pharmaceutical Co. Ltd. /Prescription Pharma Ass
Takeda Dunboyne Biologics Ltd.
Plasmaspendedienst GmbH
Takeda Belgium NV
Takeda Pharmaceutical Co. Ltd. /Non Core Assets/
Takeda Re Insurance AG
Plasmapunkt Favoriten GmbH
Takeda Malaysia Sdn. Bhd.
Takeda Pharmaceutical Co. Ltd. /Latam Bus/
Takeda Oranienburg Real Estate GmbH & Co. KG
Pvp Biologics, Inc.
Maverick Therapeutics, Inc.
Gammadelta Therapeutics Ltd.
Takeda Pharmaceutical Director Incentive Plan
Takeda Pharmaceutical Employee Incentive Plan
Oy Leiras Takeda Pharmaceuticals AB
Takeda Architectural Design Consulting (Shanghai) Co. Ltd.
Takeda Pharma AB
Takeda Development Center Americas, Inc.
Takeda Ukraine LLC
Takeda Pharmaceuticals Taiwan Ltd.
Takeda SRL
Takeda Hellas SA
Takeda Christiaens SCA/CVA
Takeda Belgium SCA/CVA

Competitors

AstraZeneca PLC
Grifols, S.A. Class A
Green Cross Corporation
Amgen Inc.
CSL Limited
Karyopharm Therapeutics, Inc.
Amicus Therapeutics, Inc.
Protalix Biotherapeutics, Inc.
ADMA Biologics, Inc.
Novartis AG
Pfizer Inc.
Johnson & Johnson
Sanofi
Mochida Pharmaceutical Co., Ltd.
AbbVie, Inc.
Merck & Co., Inc.
Organon & Co.
Roche Holding Ltd Dividend Right Cert.
Bristol-Myers Squibb Company
Bayer AG
Novo Nordisk A/S Class B
UCB S.A.
Merck KGaA
Swedish Orphan Biovitrum AB
JCR Pharmaceuticals Co., Ltd.
Supernus Pharmaceuticals, Inc.
Pharming Group NV
Oncopeptides AB
BioCryst Pharmaceuticals, Inc.
ISU Abxis Co., Ltd.

Last Updated on 27 Jan, 2023